Original article. Introduction
|
|
- Hannah Walters
- 5 years ago
- Views:
Transcription
1 Original article Annals of Oncology 14: , 2003 DOI: /annonc/mdg288 A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer K. Bouzid 1 *, S. Khalfallah 2, J. Tujakowski 3, B. Piko 4, G. Purkalne 5, S. Plate 5, P. Padrik 6, M. Serafy 7, E. M. Pshevloutsky 8 & B. Boussard 9 On behalf of the Irinotecan Study Group 1 EHS Centre Pierre et Marie Curie, Algiers, Algeria; 2 Institue Salah Azaiz Bab Saadoun, Tunis, Tunisia; 3 Regionalne Centrum Oncologii, Bydgoszcz, Poland; 4 Pandy K Bekescountry County Hospital, Gyula, Hungary; 5 Oncology Center of Latvia, Riga, Latvia; 6 Clinicum of the University of Tartu, Tartu, Estonia; 7 National Cancer Institute, Cairo, Egypt; 8 Oncology Dispanser, Omsk, Russia; 9 Global Medical Affairs Oncology, Aventis Pharma, Antony, France Received 18 October 2002; revised 13 February 2003; accepted 17 March 2003 Introduction Background: Three different therapeutic regimens of irinotecan (CPT-11) in combination with 5-fluorouracil (5-FU) and folinic acid (FA) were evaluated for efficacy and safety in the first-line therapy of advanced colorectal cancer. Patients and methods: Patients were randomly assigned to receive intravenously either: CPT mg/m 2, FA 20 mg/m 2 followed by 5-FU 500 mg/m 2 bolus, weekly for 4 weeks (arm A, Saltz regimen); or CPT mg/m 2 day 1 then FA 200 mg/m 2 over 2 h and 5-FU 400 mg/m 2 bolus and 5-FU 600 mg/m 2 22-h infusion on days 1 and 2, every 2 weeks (arm B, Douillard regimen); or CPT mg/m 2 (days 1 and 43) alternating with FA 20 mg/m 2 /day followed by 5-FU bolus 425 mg/m 2 /day during 5 days (days 22 26) (arm C, Mayo Clinic regimen). Results: A total of 154 patients were included in the study (arm A, 51 patients; arm B, 53; arm C, 50). Overall response rates for the intention-to-treat populations were 33% [95% confidence interval (CI) 21% to 48%], 42% (95% CI 28% to 56%) and 30% (95% CI 18% to 45%) for arms A, B and C, respectively. Median times to progression were 6, 8 and 7 months for arms A, B and C, respectively. Median survival times were 15, 12 and 17 months for arms A, B and C, respectively. Overall response rates for the evaluable patient populations were 40% (95% CI 24% to 58%) in arm A, 44% (95% CI 29% to 60%) in arm B and 31% (95% CI 17% to 47%) in arm C. Neutropenia was the main serious adverse event in arms A (30% of patients) and C (22% of patients) but occurred in only 8% of patients in arm B. Delayed diarrhea was the main severe adverse event for the three regimens, from 15% to 22%. Conclusion: All three regimens were highly active. The biweekly combination of CPT-11 and 5-FU/FA (arm B) was notable for its low incidence of grade 3/4 neutropenia. The incidence of grade 3/4 delayed diarrhea was equivalent for the three treatment arms. Key words: colorectal cancer, first-line, 5-fluorouracil/folinic acid, irinotecan 5-Fluorouracil (5-FU)-based chemotherapy has been the mainstay of treatment for advanced colorectal cancer for the last three decades [1]. When given alone, as an intravenous (i.v.) bolus, once weekly or for five consecutive days every 4 5 weeks, 5-FU produces response rates of between 11% and 17% and a median survival time of approximately 1 year [2]. A number of biochemical modulators have been used in combination with 5-FU in an attempt to improve its efficacy while maintaining acceptable *Correspondence to: Professor. K. Bouzid, EHS Centre Pierre et Marie Curie, Avenue Salem Bouzenad, Algiers 16005, Algeria. Tel: ; Fax: ; kamelbouzidz@yahoo.fr Additional members of the Irinotecan Study Group are listed in the Acknowledgements. toxicity. The most successful of these to date is folinic acid (FA), and regimens based on 5-FU and FA are standard in the majority of institutions worldwide [3]. Irinotecan (CPT-11) (7-ethyl-10-[4(-1-piperidino)-1-piperidino] carbonyloxy camptothecin), a semisynthetic derivative of the natural alkaloid camptothecin, was introduced into the clinic in the late 1980s. CPT-11 belongs to a new class of antineoplastic agents, the topoisomerase I-interactive compounds, which interfere with DNA replication and cell division [4]. Clinical studies with CPT-11 have demonstrated tolerable side-effects and a broad spectrum of efficacy against solid tumors, including colorectal cancer [5]. As first-line chemotherapy in metastatic colorectal cancer, single-agent CPT-11 produced a combined response rate of 26% [95% confidence interval (CI) 20% to 32%)], a median time to progression (TTP) of 8 9 months and a median survival time of 12 months [6 9]. Thus, single-agent CPT-11 demonstrates 2003 European Society for Medical Oncology
2 1107 an antitumor efficacy comparable to that achievable with standard FA-modulated 5-FU-based regimens. Furthermore, CPT-11 has demonstrated promising antitumor activity in patients with 5-FU-refractory colon cancer, producing response rates in the range of 13 23% and median times to progression of 6 8 months [9 11]. In randomized phase III trials, second-line single-agent CPT-11 extended survival significantly compared with either best supportive care [12] or infusional 5-FU and FA [13]. The most frequent adverse events associated with CPT-11 include neutropenia, delayed diarrhea, acute cholinergic syndrome, alopecia, fatigue and nausea/vomiting [9]. Based on the promising single-agent activity of CPT-11 in the treatment of colorectal cancer, it has been investigated in combination with different 5-FU-based regimens. Interesting results in terms of both efficacy and safety have been reported for CPT-11 in combination with either standard bolus or an alternating bolus 5-FU/FA schedule, or with a continuous infusional high-dose 5-FU/FA schedule as first-line therapy [14 18]. Two international (North American and European) randomized phase III trials have confirmed the efficacy of CPT-11 combined with the most frequently used 5-FU/FA bolus and infusional regimens compared with the corresponding 5-FU/FA alone [19, 20]. The combination arms of both trials demonstrated a significant superiority in terms of efficacy (response rate, median TTP and median survival time), compared with 5-FU/FA alone [19, 20]. As a result, CPT-11 in combination with either bolus 5-FU/FA or an regimen has been approved for the first-line treatment of patients with advanced or metastatic colorectal cancer in both the United States and Europe. Several studies are now ongoing in the United States and Europe to assess the efficacy and safety of the different CPT-11/5-FU/FA combinations. The present phase II randomized study of CPT-11 combined with either an infusional or bolus 5-FU/FA or alternating bolus 5-FU/FA regimen, was designed to assess the response rates of three different, but established, therapeutic CPT-11/5-FU/FA regimens in the same trial. The safety profile, median TTP and survival data were also evaluated. Patients and methods Patient eligibility Patients with histologically proven, measurable, advanced adenocarcinoma of the colon or rectum, with no potentially resectable metastases were eligible for the study. The other inclusion criteria were: age between 18 and 75 years; World Health Organization (WHO) performance status (PS) 0 2; a life expectancy >3 months; adequate hematological function (hemoglobin 10 g/dl, neutrophils /l and platelets /l); satisfactory hepatic and renal function [total bilirubin 1.25 upper normal limit (UNL), creatinine 1.25 UNL, transaminases 3 UNL; or in case of liver metastases: total bilirubin 1.5 UNL, aspartate and alanine aminotransferases 5 UNL]. Patients had to have received no prior chemotherapy, or only (neo)adjuvant chemotherapy which had ceased >6 months before randomization, and no radiotherapy within the 4 weeks before study entry. Specific exclusion criteria included a tumor type other than metastatic colorectal adenocarcinoma, except for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix, evidence of brain metastasis, current infection, unresolved bowel obstruction or subobstruction, uncontrolled Crohn s disease or ulcerative colitis, or a current history of chronic diarrhea. This study was approved by the local ethical committees of each center and was conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent. Pretreatment baseline evaluations included a complete medical history and physical examination, complete blood cell count and blood chemistry, an ECG (electrocardiography), complete tumor imaging (X-ray, computed tomography, ultrasound) and an assessment of tumor markers. Treatment CPT-11 (Campto ) was supplied by Aventis Pharma (Antony, France) as a sterile solution of 20 mg/ml in 5 ml vials. Patients were randomly assigned to receive one of three regimens: arm A, consisting of CPT mg/m 2 administered i.v. over min, FA 20 mg/m 2 administered i.v. over 15 min immediately after completion of the CPT-11 infusion and 5-FU 500 mg/m 2 administered as an i.v. bolus immediately following FA, weekly for 4 weeks on days 1, 8, 15 and 22, every 6 weeks (Saltz regimen); arm B, consisting of CPT mg/m 2 administered i.v. over min on day 1, followed immediately by FA 200 mg/m 2 administered i.v. over 2 h followed immediately by 5-FU 400 mg/m 2 administered as an i.v. bolus and 5-FU 600 mg/m 2 as a 22-h i.v. infusion on days 1 and 2, every 2 weeks (Douillard regimen); or arm C, consisting of CPT mg/m 2 administered i.v. over min on day 1 and day 43 (6 weeks) alternating with FA 20 mg/m 2 /day followed by 5-FU 425 mg/m 2 /day administered as an i.v. bolus daily for 5 days (days 22 26) (Mayo Clinic regimen). One cycle corresponded to 6 weeks for each treatment arm. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of patient consent. A cycle was considered to be delayed if the cycle duration was >6 weeks. If this duration was >8 weeks the patient was taken off study. A 20% reduction in the dose of CPT-11 and 5-FU was made in the case of grade 3/4 hematological and non-hematological toxicities, for the three arms. Concomitant medication included subcutaneous atropine (0.25 mg) as a curative treatment for severe cholinergic symptoms, including early diarrhea, which could be continued in subsequent cycles with prophylactic intent, and oral loperamide, 2 mg every 2 h, for at least 12 h as soon as the first liquid stool occurred and up to 12 h after the last liquid stool without exceeding a total treatment duration of 48 h, and oral rehydration for the curative treatment of delayed diarrhea. If diarrhea persisted for >48 h despite loperamide treatment, or in the case of severe diarrhea or diarrhea associated with vomiting, fever or severe neutropenia, prophylactic broad-spectrum oral antibiotics, with fluoroquinolone or cotrimoxazole, had to be administered for 7 days and the patient had to be hospitalized for rehydration. Patients with febrile neutropenia had to be hospitalized to receive i.v. antibiotics. No prophylactic antiemetics were allowed on day 1 of treatment, but could be used at the discretion of the investigator in subsequent cycles. Growth factor support was administered at the discretion of the investigator. Response and toxicity evaluation Tumor response was radiologically assessed every 12 weeks (or two cycles of treatment) according to WHO criteria [complete response (CR), partial response (PR), minor response, stable disease (SD) and progressive disease (PD)]. The overall response rate determined by the investigators was defined as the percentage of patients with a CR or PR. The period for CR lasted from the date the CR was achieved to the date thereafter on which PD was first noted. The period of overall response lasted from the first day of treatment to the date of first observation of PD. The duration of SD was taken from the date that SD was first recorded until the date thereafter when PD was first recorded. TTP was the time measured from the day of randomization to the first progression or death due to malignant disease. Toxicity, graded according to National Cancer Institute (NCI) Common Toxicity Criteria, was assessed before each infusion by clinical and biological examinations (before each infusion for hematology and every 6 weeks for biochemistry).
3 1108 Statistical analysis According to the single-stage Fleming design, 45 patients needed to be recruited into each arm and the sample size was not calculated for comparative analysis. The analyses were performed with SAS Software version 8.0 for Windows and S-plus V 4.5. The primary end point of the study was to evaluate the response rate of each combination, calculated with the 95% CI. The secondary efficacy criteria were the duration of response and of stabilization, TTP and survival. The times to event were estimated by the Kaplan Meier method. Efficacy analyses were performed for both the intention-to-treat (ITT) and evaluable populations (eligible patients having received at least one complete cycle of treatment, except for patients whose disease had progressed before the end of the cycle, and same method of radiological assessment during the study). The survival was evaluated for the ITT populations only. Safety analyses were performed for all patients who had received one complete cycle of CPT-11/5-FU/FA. Results Patient characteristics Between April 1998 and July 2000, 154 patients (51 patients in arm A, 53 in arm B and 50 in arm C) were randomly assigned and treated in the study in 28 centers from 16 countries (Eastern Europe, Middle East, Asia and North Africa). Sixteen patients (10%) were ineligible due to the absence of a measurable lesion (n = 3), no adequate hematological/biochemical function (n = 5), no complete initial work-up (n = 6) or first treatment not being within 8 days of randomization (n = 2). Table 1 shows the baseline characteristics of the patients, all of which were balanced across the treatment groups except for the proportion of men, which appeared greater in arm B (64% versus 43% in arm A and 52% in arm C) and for prior radiotherapy and/or adjuvant chemotherapy, which appeared more frequently in arm C (prior radiotherapy in 26% of patients versus 18% in arm A and 15% in arm B, prior adjuvant chemotherapy in 36% of patients versus 22% in arm A and 13% in arm B). However, the median number of cycles of previous adjuvant chemotherapy was similar for the three treatment groups (median of six, range from one to nine in arm A, from three to six in arm B, and from two to 26 in arm C). Approximately 80% of patients had undergone surgery before inclusion. The median age was >50 years for all treatment arms. More than 86% of the patients had a WHO PS of 0 1 at baseline. The majority of patients had one organ involved, with the liver being the most common site of metastatic disease. Dose intensity The median number of cycles administered was similar for the three treatment arms (Table 2). A total of 203 cycles were administered in arm A (weekly schedule), 222 cycles in arm B (biweekly schedule) and 208 cycles in arm C (alternating schedule). The median relative dose intensities (ratio of actual dose intensity to planned dose intensity) of CPT-11 and 5-FU were higher in the alternating schedule (94.8% and 93.2%, respectively) than in either the weekly combination of CPT-11 with bolus 5-FU/FA (83.2% and 87.5%, respectively) or the biweekly combination of CPT-11 with bolus and (85.7% and 72.7%, respectively). Approximately one-quarter of the cycles had to be delayed in each treatment arm. The most frequent reason for this was hematological toxicity in arm A, and non-study-drug-related adverse events in arms B and C. The dose had to be reduced in 8% of cycles in arm A, 6% of cycles in arm B and 13% of cycles in arm C. The most frequent reasons for this were hematological toxicity in arm A and non-hematological toxicity related to study drug in arms B and C (Table 2). Efficacy results Of the 138 eligible patients, 18 could not be assessed for response due either to deviation from the method of measurement used at baseline (17 patients) or to failure to administer a full cycle of treatment (one patient), leading to a total of 120 evaluable patients. The overall response rates were 40% (95% CI 24% to 58%) in arm A (weekly regimen), 44% (95% CI 29% to 60%) in arm B (biweekly regimen) and 31% (95% CI 17% to 47%) in arm C (alternating regimen) for the evaluable patient populations (Table 3). CRs were observed in 9% of arm A patients and 7% of arm B patients, but no CRs were reported for the alternating schedule, arm C. Similar results were obtained for the ITT populations with best overall response rates of 33% (95% CI 21% to 48%), 42% (95% CI 28% to 56%) and 30% (95% CI 18% to 45%) in arms A, B and C, respectively. The median durations of response were 8.5, 11.0 and 12.1 months in arms A, B and C, respectively for the evaluable patient population. The median durations of stabilization were 5.5, 2.7 and 5.7 months for arms A, B and C, respectively, evaluable populations (Table 3). The median TTPs were 5.8, 8.0 and 7.3 months for arms A, B and C, respectively. The Kaplan Meier estimates of TTP for the three patient groups are shown in Figure 1. The median survival times were 15.2, 12.4 and 17.0 months for arms A, B and C, respectively, ITT population (Table 3). The Kaplan Meier survival curves are shown in Figure 2. Safety results All 154 patients were evaluable for hematological and nonhematological toxicity. Hematological toxicity. Hematological toxicity (worst grade) by patient is reported in Table 4. Neutropenia was the main severe adverse event in arm A (weekly CPT-11 plus bolus 5-FU/FA regimen) and arm C (alternating regimen). Grade 3/4 toxicity occurred in 30% of patients for arm A and in 22% of patients for arm C. The incidence of neutropenia was lower in arm B patients (biweekly CPT-11 plus bolus and regimen) with the occurrence of grade 3/4 toxicity in 8% of patients. Febrile neutropenia only occurred in arm A patients (6% of patients). Grade 3/4 anemia occurred in 8% of patients in arm A, 2% of patients in arm B and 4% of patients in arm C. Grade 4 thrombocytopenia was rare, and was only reported in 2% of patients in arms A and C (and for no patients in arm B). Non-hematological toxicities. The most common non-hematological adverse events (all grades) that were possibly or probably related to the treatment were delayed diarrhea (66 78% of
4 1109 Table 1. Patient characteristics (n = 154) Characteristics Arm A, CPT-11 + bolus 5-FU/FA (n = 51) CPT-11 and 5-FU/FA (n = 50) Treated/evaluable (%) 51/35 (69%) 53/43 (81%) 50/42 (84%) Median age, years (range) 57 (20 70) 56 (24 72) 52 (23 69) Sex Male 22 (43%) 34 (64%) 26 (52%) Female 29 (57%) 19 (36%) 24 (48%) WHO performance status 0 17 (33%) 15 (28%) 16 (32%) 1 28 (55%) 31 (58%) 31 (62%) 2 6 (12%) 7 (13%) 3 (6%) Primary tumor site Colon 16 (31%) 21 (40%) 21 (42%) Rectum 21 (41%) 14 (26%) 16 (32%) Colon rectosigmoid 14 (27%) 18 (34%) 13 (26%) Organ involved Liver 38 (75%) 44 (83%) 32 (64%) Lung 12 (24%) 5 (9%) 8 (16%) Lymph node 13 (25%) 13 (25%) 13 (26%) Bone 0 2 (4%) 1 (2%) Skin 1 (2%) 0 0 Other 11 (22%) 4 (8%) 12 (24%) Other soft tissue 7 (14%) 8 (15%) 7 (14%) Median number (range) 1 (1 3) 1 (1 4) 1 (1 3) Median time from first metastasis diagnosis, months (range) 1 (0 9.8) 0.9 (0 14.6) 1.2 (0 19.4) Prior therapy Surgery 40 (78%) 43 (81%) 40 (80%) Radiotherapy 9 (18%) 8 (15%) 13 (26%) Adjuvant therapy 11 (22%) 7 (13%) 18 (36%) Radiotherapy + surgery 8 (16%) 7 (13%) 12 (24%) Radiotherapy + adjuvant therapy 6 (12%) 5 (9%) 9 (18%) Surgery + adjuvant therapy 11 (22%) 7 (13%) 18 (36%) Surgery + adjuvant therapy + radiotherapy 6 (12%) 5 (9%) 9 (18%) patients), alopecia (53 60% of patients), nausea (57 62% of patients), vomiting (45 58% of patients), anorexia (30 39% of patients), stomatitis (20 34% of patients) and cholinergic syndrome (20 32% of patients). Grade 3/4 NCI adverse events per patient (Table 5) were delayed diarrhea (18% versus 15% versus 22% of patients in arms A, B and C, respectively), grade 3/4 nausea/vomiting (equivalent in the three arms at 7 8%), grade 3/4 stomatitis (6% in arms A and C), grade 3/4 infection (low incidence of 6% in arm A, 2% in arm B, none in arm C), and low incidence of grade 3/4 cholinergic syndrome in the three arms. Grade 2 alopecia occurred in 30% versus 40% versus 54% of patients in arms A, B and C, respectively. Hepatic and renal tolerance was good. Patient withdrawal and deaths. Patients were withdrawn from the study due mainly to disease progression (47% versus 60% versus 62% of patients in arms A, B and C, respectively), and withdrawal of patient consent (20% versus 13% versus 14% of patients in arms A, B and C, respectively). At the time of analysis, 58 patients were alive. The majority of deaths were due to malignant disease, but three deaths were related to the study treatment. There were two patients in arm A, one 70-year-old patient who died of septic
5 1110 Table 2. Exposure to study medication shock 6 days after the last infusion of the first cycle and one 42-year-old patient who died of hypokalemia plus hyponatremia 3 days after the last infusion of the first cycle. The third treatmentrelated death, in arm C, was a 42-year-old patient who died 16 days after the last infusion of the fifth cycle of therapy from a cardiac arrest following grade 4 fever with infection. There were six deaths (4%) across all three treatment arms within the first 60 days of therapy. Four early deaths were reported for arm A. Two of these were considered to be treatment related as described above, and two unrelated to treatment due to malignant disease. Two early deaths (cerebral stroke, malignant disease) were also reported for arm B but both were unrelated to treatment (Table 6). Discussion Cycles Arm A, CPT-11 + bolus 5-FU/FA (n = 51) The primary objective of this multicenter open phase II study was to evaluate the efficacy of three different therapeutic regimens in which CPT-11 was combined with concomitant or alternated bolus and/or for the first-line therapy of advanced colorectal cancer. The weekly combination of CPT mg/m 2, FA 20 mg/m 2 and bolus 5-FU 500 mg/m 2 evaluated in arm A was previously shown to be feasible and well-tolerated in a phase I trial reported by Saltz et al. [14]. Neutropenia was the major dose-limiting toxicity and diarrhea was common, but rarely dose-limiting [14]. The efficacy of this regimen was confirmed by Saltz et al. [19] in their pivotal North American phase III trial that Number Median (range) 4 (1 8) 4 (1 10) 4 (1 9) Percent relative dose intensity, (median and range) CPT-11 and 5-FU/FA (n = 50) CPT (48 111) 85.7 (34 102) 94.8 (66 103) 5-FU 87.5 (49 111) 72.7 (31 100) 93.2 (52 107) FA 91.9 (49 124) 70.5 (31 149) 92.2 (52 110) No. of delayed cycles 48 (24%) 60 (27%) 49 (24%) Reason for delay Hematological 23 (48%) 8 (13%) 14 (29%) Non-hematological 7 (15%) 20 (33%) 9 (18%) Non-study-related adverse experience 13 (27%) 25 (42%) 23 (47%) Other 5 (10%) 7 (11%) 3 (6%) No. of cycles with dose modification 16 (8%) 14 (6%) 26 (13%) Reason for dose modification Hematological 9 (56%) 2 (14%) 10 (38%) Non-hematological 6 (38%) 9 (64%) 16 (62%) Hematological and non- hematological 0 2 (14%) 0 Non-study-related adverse experience 1 (6%) 1 (7%) 0 evaluated the present arm A CPT-11/week 5-FU/FA regimen versus the Mayo Clinic 5-FU/FA regimen (bolus for 5 days every 4 weeks) and versus CPT mg/m 2 alone administered weekly for 4 weeks. The overall confirmed response rate for the CPT-11/5-FU/FA arm of this phase III trial (ITT population) was 39% (n = 231), and was significantly higher than the response rate reported for the corresponding control 5-FU/FA regimen of 21% (n = 226). The confirmed response rate for CPT-11 alone was 18% (n = 226). The median duration of response was 9 months for all three arms of the trial. The median TTPs were 7.0 and 4.3 months, and the overall median survivals were 14.8 and 12.6 months for the CPT-11/5-FU/FA and 5-FU/FA arms, respectively [19]. The biweekly Douillard regimen combination of CPT mg/m 2 (5-FU/FA fixed dose: 200 mg/m 2 FA, 5-FU bolus 400 mg/m 2 and 5-FU 600 mg/m 2 over 22 h, on days 1 and 2) evaluated in arm B was previously shown to be safe in pretreated patients without overlapping toxicity in the phase I study reported by Ducreux et al. [18]. These results were confirmed by Douillard et al. [20] in a pivotal European phase III trial which evaluated CPT-11 in combination with either the biweekly de Gramont (LV5FU2) or the weekly German Arbeitsgemeinschaft Internische Onkologie 5-FU/FA infusional regimens (n = 387). The overall confirmed response rates were 35% and 22% (ITT analysis), respectively, for the CPT-11 combination arm and the 5-FU/FA control arm. Again, the median durations of response were approximately 9 months for both the CPT-11/5-FU/FA and
6 1111 Table 3. Analysis of efficacy Evaluable patients a Arm A, CPT-11 + bolus 5-FU/FA a Eighteen patients were non-evaluable for the following reasons: method of measurement different from baseline (17 patients); one did not complete a full cycle of treatment. Number Best response Complete response 3 (9%) 3 (7%) 0 Partial response 11 (31%) 16 (37%) 13 (31%) Minor response/stable disease 12 (34%) 13 (30%) 19 (45%) Progressive disease 9 (26%) 11 (26%) 10 (24%) CPT-11 and 5-FU/FA Overall response rate 40% (24% to 58%) 44% (29% to 60%) 31% (17% to 47%) Tumor growth control rate 74% 74% 76% Median duration of stabilization, months Median response duration, months Median time to progression, months Intention-to treat patients 5.5 ( 7.3) 2.76 ( ) 5.7 ( ) 8.5 ( ) 11.0 ( ) 12.1 ( ) 5.8 ( ) 8.0 ( ) 7.3 ( ) Number Overall response rate 33% (21% to 48%) 42% (28% to 56%) 30% (18% to 45%) Median time to progression, months Median response duration, months Median survival time, months 6.1 ( ) 7.9 ( ) 7.2 ( ) 8.5 ( ) 11.0 ( ) 11.5 ( ) 15.2 ( ) 12.4 ( ) 17.0 ( ) 5-FU/FA arms [20]. The median TTPs were 6.7 and 4.2 months, and median survival times 17.4 and 14.1 months for the CPT-11/ 5-FU/FA and 5-FU/FA arms, respectively [20]. The alternating schedule of CPT-11 (350 mg/m 2 ) day 1 with FA (20 mg/m 2 /day) followed by 5 days bolus of 5-FU (425 mg/m 2 /day) (Mayo Clinic regimen) evaluated in arm C was previously reported by Van Cutsem et al. [16] in a phase II trial, and was shown to have a good tolerability profile, without any cumulative or overlapping toxicity. The present study showed that all three of the CPT-11/5-FU/FA combination regimens were highly active and comparable in terms of overall response rates (from 31% to 44% in the evaluable populations, and 30% to 42% in the ITT populations), median duration of response ( months) and median TTP (6 8 months) for the evaluable population, and median survival times [12 17 months (ITT)]. The study populations were representative of the candidates for first-line chemotherapy seen in clinical practice in both western Europe and the Unites States and the efficacy data were consistent with the efficacy data from the USA and European pivotal phase III trials [19, 20]. In previous phase II trials of the alternating schedules of bolus 5-FU/FA (Mayo Clinic regimen) and CPT-11 given either on a weekly-times-four schedule at 100 mg/m 2 [15] or every 6 weeks at 350 mg/m 2 [16] similar efficacy was shown with overall response rates of approximately 30% and median survival times of between 16 and 18 months. The three combinations of CPT-11 plus 5-FU and FA were well-tolerated and the toxic effects reversible, non-cumulative and manageable. Consistent with the observations made in previous studies, neutropenia and delayed diarrhea were the most common toxic effects. Neutropenia was the main severe adverse event occurring in the weekly CPT-11 plus bolus 5-FU/FA regimen and in the alternating regimen, as already observed in previous trials. Saltz et al. [19] reported grade 3/4 neutropenia in 54% of patients using the weekly regimen (n = 225). This was higher than our experience in the present study (30% of patients with grade 3/4 neutropenia). Similarly, Van Cutsem et al. [16], using the alternating schedule, reported 64% of patients with grade 3/4 neutropenia (n = 33), which was higher than that reported in the present trial (22% of grade 3/4 neutropenia). However, the frequency of severe neutropenia was higher (46% of grade 3/4 toxicity) in the European randomized phase III study than in the present study (8% grade 3/4 toxicity) [20]. The incidence of grade 3/4 delayed diarrhea was approximately 20% in arms A and C (18% for the weekly schedule and 22% for the alternating regimen),
7 1112 Figure 1. Kaplan Meier estimate of time to progression (intention-to treat population). Figure 2. Kaplan Meier estimate of overall survival (intention-to-treat population). which was comparable to the previously reported data [16, 19]. Delayed diarrhea also occurred in the biweekly schedule combining CPT-11 with bolus and, with 15% of patients exhibiting grade 3/4 toxicity. This incidence of severe diarrhea was similar to that observed in the European randomized phase III study, and was well managed by following the antidiarrheal guidelines with intensive and early use of loperamide. However, this regimen was distinguishable from the other two regimens by virtue of the very low incidence of grade 3/4 neutropenia (8% of patients and 2% of cycles).
8 1113 Table 4. Hematological toxicity (numbers of patients) related to CPT-11 and 5-FU/folinic acid treatments (worst grade by patient) Neutropenia Arm A, CPT-11 + bolus 5-FU/FA (n = 51) Overall 35 (69%) 25 (49%) 30 (60%) Grade 3 8 (16%) 2 (4%) 7 (14%) Grade 4 7 (14%) 2 (4%) 4 (8%) Febrile neutropenia a 3 (6%) 0 0 Leukopenia Overall 36 (71%) 26 (51%) 23 (46%) Grade 3 6 (12%) 0 6 (12%) Grade 4 1 (2%) 0 2 (4%) Thrombocytopenia Overall 4 (8%) 1 (2%) 2 (4%) Grade 4 1 (2%) 0 1 (2%) Anemia Overall 32 (63%) 39 (76%) 31 (62%) Grade 3 3 (6%) 1 (2%) 2 (4%) Grade 4 1 (2%) 0 0 CPT-11 and 5-FU/FA (n = 50) a Defined as fever 38 C concomitant with a grade 3/4 neutropenia in the absence of documented infection. Table 5. Number of patients (and percentage) with grade 3/4 non-hematological toxicity related to CPT-11 and 5-FU/FA treatments (n = 154) Toxicity Arm A, CPT-11 + bolus 5-FU/FA (n = 51) Alopecia grade 2 15 (30%) 21 (40%) 27 (54%) Diarrhea 9 (18%) 8 (15%) 11 (22%) Vomiting 4 (8%) 4 (8%) 4 (8%) Nausea 3 (6%) 3 (6%) 4 (8%) Stomatitis 3 (6%) 0 3 (6%) Infection 3 (6%) 1 (2%) 0 Cholinergic syndrome 1 (2%) 0 1 (2%) CPT- 11 and 5-FU/FA (n = 50) The other severe non-hematological toxicities occurred at a low incidence in all treatment arms and included mainly alopecia, and nausea/vomiting. No case of severe stomatitis was noted in the biweekly regimen, while 6% of patients experienced grade 3/4 toxicity in both the weekly regimen and the alternating regimen. The occurrence of cholinergic syndrome was low in all three arms. In conclusion, the three different therapeutic regimens combining CPT-11 with concomitant (weekly or biweekly) or alternated bolus and/or were highly active in patients with advanced colorectal cancer, and were associated with an easily managed safety profile, which ensured good schedule compliance. The low incidence of grade 3/4 neutropenia observed with the biweekly combination of CPT-11 and 5-FU/FA (arm B), means that this regimen has the best tolerability profile of the three regimens tested. Acknowledgements We are indebted to N. Cussac for diligent writing support and meticulous data review, as well as to B. Raoult and M. Berlion. This work was supported by Aventis Pharma, Antony, France and was presented in preliminary forms at the 20th Annual Meeting of
9 1114 Table 6. Death (numbers of patients) related or unrelated to study treatment within 60 days after the first infusion Death Arm A, CPT-11 + bolus 5-FU/FA (n = 51) Treatment-induced 2 (4%) 0 0 Treatment-unrelated 2 (4%) 2 (4%) 0 CPT- 11 and 5-FU/FA (n = 50) the American Society of Clinical Oncology, May 2000, New Orlean, and at the 21st Annual Meeting of the American Society of Clinical Oncology, May 2001, San Francisco. Additional principal participating investigators of the Irinotecan Study Group were: P. P. Bapsy (India), S. Ben Ahmed (Tunisia), T. Salek (Slovakia), S. Donea (Romania), D. A. Gerges (Lebanon), D. C. Doval (India), E. Buyukunal (Turkey), I. N. Chernozemsky (Bulgaria), V. I. Tzekova (Bulgaria), H. A. El-Azim (Egypt), H. Errihani (Morocco), R. Samlali (Morocco), J. S. Godz (Poland), N. Ghilezan (Romania), B. A. Berdov (Russia), G. N. Tchaikovsky (Russia), M. Wagnerova (Slovakia), N. F. Aykan (Turkey), J. Zidan (Israel) and G. Chachine (Lebanon). References 1. Machover D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer 1997; 80: Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994; 12: Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 1994; 20: Rothenberg ML. Topoisomerase I inhibitors: review and update. Ann Oncol 1997; 8: Conti J, Kemeny N, Saltz L et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996; 14: Pitot HC, Wender DB, O Connell M et al. Phase II trial irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997; 15: Rougier P, Bugat R, Douillard J et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and pretreated patients with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: Vanhoefer U, Harstrick A, Achterrath W et al. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 2001; 19: Rothenberg M, Eckardt J, Kuhn J et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996; 14: Van Cutsem E, Cunningham D, Ten Bokkel Huinink WW et al. Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU). Eur J Cancer 1999; 35: Cunningham D, Pyrhönen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: Rougier P, Van Custem E, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after failure in patients with metastatic colorectal cancer. Lancet 1998; 352: Saltz LB, Kanowitz J, Kemeny NE et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 1996; 14: Rothenberg ML, Pazdur R, Rowinsky EK et al. A phase II multicenter trial of alternating cycles of irinotecan and 5-FU/LV in patients with previously untreated metastatic colorectal cancer. Proc Am Soc Clin Oncol 1997; 16: 266a (Abstr 944). 16. Van Cutsem E, Pozzo C, Starkhammar H et al. A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first line chemotherapy of metastatic colorectal cancer. Ann Oncol 1998; 9: Vanhoefer U, Harstrick A, Köhne CH et al. Phase I study of a weekly schedule of irinotecan, high dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol 1999; 17: Ducreux M, Ychou M, Seitz JF et al. Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a dose finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. J Clin Oncol 1999; 17: Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343: Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:
Irinotecan (CPT-11) in Patients with Advanced Colon Carcinoma Relapsing after 5-Fluorouracil-Leucovorin Combination
Clinical Report Chemotherapy 2002;48:94 99 Irinotecan (CPT-11) in Patients with Advanced Colon Carcinoma Relapsing after 5-Fluorouracil-Leucovorin Combination N.B. Tsavaris a A. Polyzos b K. Gennatas c
More informationUpdate on Chemotherapy for Advanced Colorectal Cancer
Review Article [1] March 02, 2001 By Daniel G. Haller, MD [2] Efforts to improve the length and quality of life, as well as to expand treatment options, for patients with metastatic colorectal cancer have
More informationOriginal article. E. Mitry 1 *, J.-Y. Douillard 2, E. Van Cutsem 3, D. Cunningham 4, E. Magherini 5, D. Mery-Mignard 5, L. Awad 5 & P.
Original article Annals of Oncology 15: 1013 1017, 2004 DOI: 10.1093/annonc/mdh267 Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients
More informationIntegrating Oxaliplatin into the Management of Colorectal Cancer
Integrating Oxaliplatin into the Management of Colorectal Cancer HANS-JOACHIM SCHMOLL, a JIM CASSIDY b a Martin-Luther-University Halle-Wittenberg, Halle, Germany; b University of Aberdeen, Aberdeen, UK
More informationPhase I study of postoperative radiotherapy with concomitant weekly irinotecan, 5- fluorouracil and folinic acid in locally advanced rectal cancer.
Journal of BUON 9: 255-261, 2004 2004 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Phase I study of postoperative radiotherapy with concomitant weekly irinotecan, 5- fluorouracil and
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationAdjuvant therapies for large bowel cancer Wasantha Rathnayake, MD
LEADING ARTICLE Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD Consultant Clinical Oncologist, National Cancer Institute, Maharagama, Sri Lanka. Key words: Large bowel; Cancer; Adjuvant
More informationKey words: advanced colorectal cancer, metastatic, irinotecan, 5-fluorouracil, leucovorin.
Original Article 297 Decreasing Dosage of Irinotecan, 5-Flurouracil (5-FU) and Leucovorin (LV) in the Treatment of Advanced and /or Metastatic Colorectal Cancer: A Phase II Study Jen-Seng Huang, MD; Cho-Li
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationIrinotecan. Class:Camptothecin. Indications : _Cervical cancer. _CNS tumor. _Esophageal cancer. _Ewing s sarcoma. _Gastric cancer
Irinotecan Class:Camptothecin Indications : _Cervical cancer _CNS tumor _Esophageal cancer _Ewing s sarcoma _Gastric cancer _Nonsmall cell lung cancer _Pancreatic cancer _Small cell lung cancer _Colorectal
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationBelotecan and Cisplatin Combination Chemotherapy for Previously Untreated Extensive-Disease Small Cell Lung Cancer
J Lung Cancer 2010;9(1):15-19 Belotecan and Cisplatin Combination Chemotherapy for Previously Untreated Extensive-Disease Small Cell Lung Cancer Purpose: Belotecan (Camtobell R ; Chong Keun Dang Co., Seoul,
More informationReview. A. Di Leo 1 *, M. Buyse 2 & H. Bleiberg 1. Introduction. Design and main results of the trials
Review Annals of Oncology 15: 545 549, 2004 DOI: 10.1093/annonc/mdh127 Is overall survival a realistic primary end point in advanced colorectal cancer studies? A critical assessment based on four clinical
More informationBMC Cancer. Open Access. Abstract. BioMed Central
BMC Cancer BioMed Central Research article Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer Thomas
More informationPRODUCT INFORMATION 1 ABOUT THIS GUIDE DOSAGE FORM AND STRENGTH STORAGE AND HANDLING
DOSING GUIDE INDICATION ONIVYDE (irinotecan liposome injection) is indicated, in combination with fluorouracil (5-FU) and leucovorin (LV), for the treatment of patients with metastatic adenocarcinoma of
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationClinical Guidelines for Managing Topotecan-Related Hematologic Toxicity
Clinical Guidelines for Managing Topotecan-Related Hematologic Toxicity DEBORAH ARMSTRONG, SEAMUS O REILLY Johns Hopkins Oncology Center, Baltimore, Maryland, USA Key Words. Topotecan Topoisomerase I inhibitor
More informationCetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS)
Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer: a large-scale Phase II study (OPUS) C Bokemeyer, E Staroslawska, A Makhson, I Bondarenko, JT Hartmann,
More informationCLINICAL INVESTIGATION
Research Article CLINICAL INVESTIGATION Research on the treatment of metastatic colon cancer patients treated by FOLFOXIRI: Efficacy and toxicity of first-line treatment in stage IV metastatic colorectal
More informationVinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trial
Original article Annals of Oncology 14: 699 703, 2003 DOI: 10.1093/annonc/mdg199 Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II
More informationSponsor / Company: Sanofi Drug substance(s): SAR (iniparib)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationOriginal article. P. Rougier 1 *, D. Lepille 2, J. Bennouna 3, A. Marre 4, M. Ducreux 5, L. Mignot 6, A. Hua 7 & D. Méry-Mignard 7.
Original article Annals of Oncology 13: 1558 1567, 2002 DOI: 10.1093/annonc/mdf259 Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 November 2006 TAXOTERE 20 mg, concentrate and solvent for infusion in single-dose vials of 7 ml, individually packed
More informationOriginal article. Introduction
Original article Annals of Oncology 13: 716 720, 2002 DOI: 10.1093/annonc/mdf091 Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationOWa 22 80) :IEZ
Clinical Study Report: 20025409 Part 2 Date: 22 September 2008 OWa 22 80) 06 --- :IEZ Page 1 SYNOPSIS Name of the Sponsor: Name of Finished Product: Name of Active Ingredient: Immunex Corporation Panitumumab
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationFOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell Italia Meridionale (GOIM)
Annals of Oncology 16 (Supplement 4): iv56 iv60, 2005 doi:10.1093/annonc/mdi909 FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell Italia Meridionale (GOIM) E.
More informationGourgou-Bourgade, et al DOI: /JCO
Impact of FOLFIRINO compared with gemcitabine on Quality-of-Life in Patients with Metastatic Pancreatic Cancer: results from the PRODIGE 4/ACCORD 11 randomized trial Gourgou-Bourgade, et al DOI: 10.1200/JCO.2012.44.4869
More informationGemcitabine and Carboplatin in Patients with Refractory or Progressive Metastatic Breast Cancer after Treatment
DOI: 10.18056/seci2014.6 Gemcitabine and Carboplatin in Patients with Refractory or Progressive Metastatic Breast Cancer after Treatment Zedan A 1, Soliman M 2, Sedik MF 1 1 Medical Oncology Department,
More informationTopotecan: An Oncologist s View
Topotecan: An Oncologist s View JEAN-FRANÇOIS HÉRON Centre François Baclesse, Centre Régional de Lutte Contre le Cancer, Caen, France Key Words. Topotecan Clinical trials Ovarian neoplasms Small cell lung
More informationDALLA CAPECITABINA AL TAS 102
DALLA CAPECITABINA AL TAS 102 Milano 29 settembre 2016 LE PROSPETTIVE NELLA RICERCA Armando Santoro Humanitas Cancer Center THE 1,2.AND 3 LINE CHEMOTHERAPY IN CRC M BEVACIZUMAB AFLIBERCET RAS wt RAS mu
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.
More informationRetrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal patients in the adjuvant setting
ORIGINAL ARTICLE CAPOX AND mfolfox6 DOSE INTENSITY AND CLINICAL OUTCOMES IN STAGE III CRC, Mamo et al. Retrospective analysis of the effect of CAPOX and mfolfox6 dose intensity on survival in colorectal
More informationONCOLOGY LETTERS 2: , 2011
ONCOLOGY LETTERS 2: 241-245, 2011 Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following
More informationTumors in the Randomized German AIO study KRK-0306
FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First- Line Treatment for Patients with Metastatic Colorectal Cancer (mcrc): Analysis of Patients with KRAS-Mutated Tumors in the Randomized German
More informationLipoplatin monotherapy for oncologists
Lipoplatin monotherapy for oncologists Dr. George Stathopoulos demonstrated that Lipoplatin monotherapy against adenocarcinomas of the lung can have very high efficacy (38% partial response, 43% stable
More informationCurrent Status of Adjuvant Therapy for Colorectal Cancer
Review Article [1] May 01, 2004 By Michael J. O connell, MD [2] Adjuvant therapy with chemotherapy and/or radiation therapy in addition to surgery improves outcome for patients with high-risk carcinomas
More informationChemotherapy options and outcomes in older adult patients with colorectal cancer
Critical Reviews in Oncology/Hematology 72 (2009) 155 169 Chemotherapy options and outcomes in older adult patients with colorectal cancer Muhammad W. Saif a,, Stuart M. Lichtman b a Yale University School
More informationPfizer Laboratories (Pty) Ltd Campto 40 mg/2ml and 100 mg/5ml Approved PI: 13 Oct 2005 Page 1 of 11
Approved PI: 13 Oct 2005 Page 1 of 11 SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): CAMPTO 40 mg/2 ml Solution for Infusion CAMPTO 100 mg/5 ml Solution for Infusion COMPOSITION: Single-dose
More informationPlattenepithelkarzinom des Ösophagus, 1 st -line
Plattenepithelkarzinom des Ösophagus, 1 st -line AIO-STO-0309 An open-label, randomized phase III trial of cisplatin and 5-fluorouracil with or without panitumumab for patients with nonresectable, advanced
More informationClinialTrials.gov Identifier: sanofi-aventis. Sponsor/company: Date: 18 February 2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationBCCA Protocol Summary for Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Capecitabine and Radiation Therapy
BCCA Protocol Summary for Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Capecitabine and Radiation Therapy Protocol Code: Tumour Group: Contact Physician: GIRCRT Gastrointestinal
More informationSingle Agent Irinotecan for The Treatment of Metastatic or Recurrent Squamous Carcinoma of the Head and Neck (SCCHN)
ORIGINAL RESEARCH Single Agent Irinotecan for The Treatment of Metastatic or Recurrent Squamous Carcinoma of the Head and Neck (SCCHN) 1 Gilbert J, 1 Dang T, 2 Cmelak A, 3 Shyr Y, 4 Netterville J, 4 Burkey
More informationOriginal Paper. Clinical Activity and Bene t of Irinotecan (CPT-11) in Patients with Colorectal Cancer Truly Resistant to 5-Fluorouracil (5-FU)
Pergamon European Journal of Cancer, Vol. 35, No. 1, pp. 54±59, 1999 # 1999 Elsevier Science Ltd. All rights reserved Printed in Great Britain 0959-8049/99/$ - see front matter PII: S0959-8049(98)00353-0
More information/m 2 Oxaliplatin 85 1 Q2W 1-3 Leucovorin Q2W 5-FU Q2W 5-FU Q2W
癌症診療指引33 Adjuvant therapy of colon cancer mfolfox6 Oxaliplatin 85 1 Q2W 1-3 FOLFOX4 Oxaliplatin 85 1 Q2W 9 Leucovorin 200 1-2 Q2W 5-FU 400 1-2 Q2W 5-FU 600 1-2 Q2W FLOX Oxaliplatin 85 1,15,29 Q8W 4 Leucovorin
More informationAdjuvant Chemotherapy for Patients with Resected Dukes C and High-risk B2 Colon Cancer with Fluorouracil and Levamisole
733 Adjuvant Chemotherapy for Patients with Resected Dukes C and High-risk B2 Colon Cancer with Fluorouracil and Levamisole E Au,*FAMS, M Med (Int Med), MRCP, P T Ang,**FAMS, FACP, FRCP (Edin), F Seow-Choen,***FAMS,
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationCase Report Management of a Patient with Metastatic Colorectal Cancer and Liver Metastases
Case Reports in Oncological Medicine, Article ID 790192, 4 pages http://dx.doi.org/10.1155/2014/790192 Case Report Management of a Patient with Metastatic Colorectal Cancer and Liver Metastases Muhammad
More informationSponsor/Company: sanofi-aventis Drug substance: Elitek/Fasturtec (rasburicase, SR29142)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor/Company: sanofi-aventis Drug
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib
More informationLow Dose Docetaxel Combined With Low Dose Capecitabine in Treatment of Metastatic Breast Cancer Previously Treated With Anthracycline
Low Dose Docetaxel Combined With Low Dose Capecitabine in Treatment of Metastatic Breast Cancer Previously Treated With Anthracycline Rabab Mahmoud and Omnia Abd-elfattah Clinical Oncology Department,
More informationThree-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study
Original article Annals of Oncology 13: 1080 1086, 2002 DOI: 10.1093/annonc/mdf186 Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study H. Soto Parra
More informationTrabectedin in ASTS. Le Cesne A, et al. J Clin Oncol. 2018;36(suppl): Abstract
Results of a Prospective Randomized Phase III T-SAR Trial Comparing Trabectedin vs Best Supportive Care (BSC) in Patients With Pretreated Advanced Soft Tissue Sarcoma (ASTS) Abstract 11508 Le Cesne A,
More informationChemotherapy of colon cancers
Chemotherapy of colon cancers Stage distribution Stage I : 15% T 1,2 NO Stage IV: 20 25% M+ Stage II : 20 30% T3,4 NO Stage III N+: 30 40% clinical stages I, II, or III colon cancer are at risk for having
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationSequential Dose-Dense Adjuvant Therapy With Doxorubicin, Paclitaxel, and Cyclophosphamide
Sequential Dose-Dense Adjuvant Therapy With Doxorubicin, Paclitaxel, and Cyclophosphamide Review Article [1] April 01, 1997 By Clifford A. Hudis, MD [2] The recognition of paclitaxel's (Taxol's) activity
More informationPhase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer
Original article Annals of Oncology 13: 1862 1867, 2002 DOI: 10.1093/annonc/mdf308 Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer V.
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationNCCP Chemotherapy Regimen
Modified Roswell Park (Fluorouracil 500mg/m 2 and Folinic Acid 50mg weekly x 6) Regimen INDICATIONS FOR USE: Regimen INDICATION ICD10 Code Treatment of metastatic colorectal cancer C18 00427a Adjuvant
More informationComparative Efficacy of Adjuvant Chemotherapy in Patients With Dukes B Versus Dukes C Colon Cancer: Results From
Comparative Efficacy of Adjuvant Chemotherapy in Patients With Dukes B Versus Dukes C Colon Cancer: Results From Four National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C-03,
More informationOUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER
& OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina
More informationConcomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study
Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study T Sridhar 1, A Gore 1, I Boiangiu 1, D Machin 2, R P Symonds 3 1. Department of Oncology, Leicester
More informationSupplementary Online Content
Supplementary Online Content Powles T, O Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 openlabel
More informationOriginal article. 5-Fluorouracil versus 5-fluorouracil plus a-interferon as treatment of metastatic colorectal carcinoma. A randomized study*
Annals of Oncology 7: 575-579, 1996. O 1996 Kluwer Academic Publishers. Printed in the Netherlands. Original article 5-Fluorouracil versus 5-fluorouracil plus a-interferon as treatment of metastatic colorectal
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationNCCP Chemotherapy Regimen
QUASAR (Modified) Fluorouracil (370mg/m 2 ) and Folinic Acid (50mg) Weekly INDICATIONS FOR USE: Regimen INDICATION ICD10 Code Treatment of metastatic colorectal cancer C18 00428a Adjuvant treatment of
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy
More informationOriginal article. Introduction
Gastric Cancer (2009) 12: 153 157 DOI 10.1007/s10120-009-0517-8 Original article 2009 by International and Japanese Gastric Cancer Associations Efficacy of sequential methotrexate and 5-fluorouracil (MTX/5FU)
More informationDisclosures. Colorectal Cancer Update GAFP November Risk Assessment. Colon and Rectal Cancer The Challenge. Issues in Colon and Rectal Cancer
Disclosures Colorectal Cancer Update GAFP November 2006 Robert C. Hermann, MD Georgia Center for Oncology Research and Education Northwest Georgia Oncology Centers, PC WellStar Health System Marietta,
More informationA. Azmy, 1 S. Abdelwahab, 2 and M. Yassen Introduction
ISRN Oncology Volume 2013, Article ID 358538, 6 pages http://dx.doi.org/10.1155/2013/358538 Clinical Study Oxaliplatin and Bolus-Modulated 5-Fluorouracil as a Second-Line Treatment for Advanced Pancreatic
More informationMETRIC Study Key Eligibility Criteria
The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care
More informationOriginal article. Introduction. survival times (MSTs) from 8 to 11 months in this patient population
Original article Annals of Oncology 14: 709 714, 2003 DOI: 10.1093/annonc/mdg213 Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive
More informationMaterials and Methods
RESEARCH ARTICLE Comparative Analysis of the Efficacy and Safety of Oxaliplatin Plus 5-Fluorouracil/Leucovorin (Modified FOLFOX6) with Advanced Gastric Cancer Patients having a Good or Poor Performance
More informationDocetaxel + Nintedanib
Docetaxel + Nintedanib Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Second
More informationTo assess safety profiles: significant laboratory changes and adverse events (AEs).
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationSetting The setting was secondary care. The economic study was carried out in the UK.
Cost-utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer Robinson P, von der Masse H, Bhalla S, Kielhorn A, Aristides M, Brown A, Tilden D
More informationChemotherapy for resectable liver mets: Options and Issues. Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA
Chemotherapy for resectable liver mets: Options and Issues Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA Chemotherapy regimens in 1 st line mcrc Standard FOLFOX-Bev FOLFIRI-Bev
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationDisclosures. Clinical and molecular features to guide adjuvant therapy. Personalized Medicine - Decision Tools -
Disclosures Clinical and molecular features to guide adjuvant therapy Daniel Sargent Professor of Biostatistics & Oncology Mayo Clinic Consulting activities Amgen Pfizer Roche/Genentech Sanofi-Aventis
More informationJonathan Dickinson, LCL Xeloda
Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy
More informationRandomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer This is a two-arm, randomized phase II trial for patients with BRAF mutant
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationPatients with Renal Impairment: Use caution and do not use in or shortly after infusion of CAMPTOSAR) is usually transient and may
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CAMPTOSAR safely and effectively. See full prescribing information for CAMPTOSAR. CAMPTOSAR (Irinotecan)
More informationCombination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine
Gastric Cancer (2008) 11: 201 205 DOI 10.1007/s10120-008-0484-5 Original article 2008 by International and Japanese Gastric Cancer Associations Combination chemotherapy with cisplatin and irinotecan in
More informationA Single-Center Phase 2 Trial. Bevacizumab is a humanized immunoglobulin G1 murine antibody directed against all isoforms of
Bevacizumab in Association With de Gramont 5-Fluorouracil/Folinic Acid in Patients With Oxaliplatin-, Irinotecan-, and Cetuximab-Refractory Colorectal Cancer A Single-Center Phase 2 Trial Bruno Vincenzi,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: TAG IDAG Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationAdjuvant chemotherapy outcomes in patients over 65 years with early stage colorectal carcinoma
JBUON 2014; 19(4): 906-912 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Adjuvant chemotherapy outcomes in patients over 65 years with early
More informationThis was a multi-center study conducted at 44 study centers. There were 9 centers in the United States and 35 centers in Europe.
Protocol CAM307: A Phase 3 Study to Evaluate the Efficacy and Safety of Frontline Therapy with Alemtuzumab (Campath ) vs Chlorambucil in Patients with Progressive B-Cell Chronic Lymphocytic Leukemia These
More informationMEET ROY*: A PATIENT WITH LIVER-LIMITED mcrc
MEET ROY*: A PATIENT WITH LIVER-LIMITED mcrc * A hypothetical case study of a patient eligible for first-line mcrc therapy. mcrc = metastatic colorectal cancer. WHAT CLINICAL CHARACTERISTICS AFFECT YOUR
More informationFOLFOX-4 as second-line therapy after failure of gemcitabine and platinum combination in advanced gall bladder cancer patients
Japanese Journal of Clinical Oncology, 2016, 46(1) 57 62 doi: 10.1093/jjco/hyv148 Advance Access Publication Date: 24 November 2015 Original Article Original Article FOLFOX-4 as second-line therapy after
More informationSmall cell lung cancer (SCLC) comprises approximately
Original Article Efficacy and Toxicity of Belotecan for Relapsed or Refractory Small Cell Lung Cancer Patients Gun Min Kim, MD,* Young Sam Kim, MD, PhD, Young Ae Kang, MD, PhD, Jae-Heon Jeong, MD, Sun
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationFollow this and additional works at: Part of the Neoplasms Commons
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Will the Addition of Oxaliplatin to 5-Fluorouracil
More informationCitation Cancer Management and Research, 2(1
NAOSITE: Nagasaki University's Ac Title Author(s) Efficacy and safety of amrubicin hy small cell lung cancer Ogawara, Daiki; Fukuda, Minoru; Nak Citation Cancer Management and Research, 2(1 Issue Date
More informationAccepted 12 April 2006 Published online 13 November 2006 in Wiley InterScience ( DOI: /hed.
ORIGINAL ARTICLE PHASE II ANALYSIS OF PACLITAXEL AND CAPECITABINE IN THE TREATMENT OF RECURRENT OR DISSEMINATED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK REGION Jens D Bentzen, MD, 1 Hanne Sand Hansen,
More information